Edwards Lifesciences Corporation (EW) 10-Year Financial Performance & Capital Metrics

EW • • Industrial / General

HealthcareMedical DevicesCardiovascular DevicesStructural Heart & Valve Devices

AboutEdwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides the PASCAL and Cardioband transcatheter valve repair systems for minimally-invasive therapy. In addition, it offers surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; KONECT RESILIA, a pre-assembled aortic tissue valved conduit for patients who require replacement of the valve, root, and ascending aorta; and HARPOON Beating Heart Mitral Valve Repair System for patients with degenerative mitral regurgitation. Further, the company provides critical care solutions, including advanced hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.Show more

Revenue $5.44B +8.6%
EBITDA $1.53B -2.4%
Net Income $4.17B +197.7%
EPS (Diluted) 6.97 +203.0%
Gross Margin 79.46% +0.2%
EBITDA Margin 28.2% -10.1%
Operating Margin 25.35% -11.0%
Net Margin 76.75% +174.2%
ROE 49.75% +122.2%
ROIC 14.78% -17.1%
Debt/Equity 0.07 -31.8%
Interest Coverage 69.63 -14.1%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Excellent 3Y average ROE of 32.8%
✓Strong 5Y profit CAGR of 31.9%
✓Strong Piotroski F-Score: 7/9
✓Healthy 5Y average net margin of 36.1%
✓Trading near 52-week high

✗Weaknesses

✗Low quality earnings: Net income not backed by cash flow

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y8.88%

5Y4.58%

3Y1.3%

TTM10.25%

Profit (Net Income) CAGR

10Y17.8%

5Y31.87%

3Y40.56%

TTM-67.17%

EPS CAGR

10Y18.75%

5Y33.56%

3Y43.07%

TTM-66.52%

ROCE

10Y Avg21.27%

5Y Avg20.12%

3Y Avg18.52%

Latest13.98%

Peer Comparison

Structural Heart & Valve Devices

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
LIVNLivaNova PLC	3.35B	61.33	52.87	8.66%	-16.12%	-18.79%	4.06%	0.51
ABTAbbott Laboratories	216.14B	124.30	16.27	4.59%	31.88%	27.26%	2.94%	0.32
EWEdwards Lifesciences Corporation	48.65B	83.84	12.03	8.57%	23.19%	13.37%	0.6%	0.07
AVRAnteris Technologies Global Corp.	184.98M	4.49	-1.19	-1.16%	-39.42%	-25.1%		0.02

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	2.49B	2.96B	3.44B	3.72B	4.35B	4.39B	5.23B	5.38B	5.01B	5.44B
Revenue Growth %	0.07%	0.19%	0.16%	0.08%	0.17%	0.01%	0.19%	0.03%	-0.07%	0.09%
Cost of Goods Sold+	684.3M	805.8M	882.9M	922.1M	1.16B	1.1B	1.23B	1.17B	1.04B	1.12B
COGS % of Revenue	0.27%	0.27%	0.26%	0.25%	0.27%	0.25%	0.23%	0.22%	0.21%	0.21%
Gross Profit+	1.81B	2.16B	2.55B	2.8B	3.19B	3.29B	4.01B	4.22B	3.97B	4.32B
Gross Margin %	0.73%	0.73%	0.74%	0.75%	0.73%	0.75%	0.77%	0.78%	0.79%	0.79%
Gross Profit Growth %	0.07%	0.19%	0.18%	0.1%	0.14%	0.03%	0.22%	0.05%	-0.06%	0.09%
Operating Expenses+	1.23B	1.34B	1.54B	1.71B	1.99B	1.99B	2.4B	2.51B	2.55B	2.94B
OpEx % of Revenue	0.49%	0.45%	0.45%	0.46%	0.46%	0.45%	0.46%	0.47%	0.51%	0.54%
Selling, General & Admin	850.4M	900.2M	989.7M	1.09B	1.24B	1.23B	1.49B	1.57B	1.58B	1.79B
SG&A % of Revenue	0.34%	0.3%	0.29%	0.29%	0.29%	0.28%	0.29%	0.29%	0.32%	0.33%
Research & Development	383.1M	442.2M	552.6M	622.2M	752.7M	760.7M	903.1M	945.2M	962.9M	1.05B
R&D % of Revenue	0.15%	0.15%	0.16%	0.17%	0.17%	0.17%	0.17%	0.18%	0.19%	0.19%
Other Operating Expenses	0	0	0	0	0	0	0	0	0	101.1M
Operating Income+	575.9M	815.5M	1.01B	1.09B	1.2B	1.3B	1.61B	1.7B	1.43B	1.38B
Operating Margin %	0.23%	0.28%	0.29%	0.29%	0.28%	0.3%	0.31%	0.32%	0.28%	0.25%
Operating Income Growth %	0.18%	0.42%	0.24%	0.08%	0.1%	0.08%	0.24%	0.06%	-0.16%	-0.03%
EBITDA+	641.7M	886.7M	1.09B	1.17B	1.31B	1.43B	1.77B	1.87B	1.57B	1.53B
EBITDA Margin %	0.26%	0.3%	0.32%	0.31%	0.3%	0.33%	0.34%	0.35%	0.31%	0.28%
EBITDA Growth %	0.15%	0.38%	0.23%	0.07%	0.12%	0.09%	0.24%	0.05%	-0.16%	-0.02%
D&A (Non-Cash Add-back)	65.8M	71.2M	81.9M	77.4M	114.6M	135.4M	163.3M	166.8M	144.9M	155.2M
EBIT	640.8M	755.9M	1.06B	794.8M	1.19B	938.9M	1.73B	1.79B	1.39B	1.57B
Net Interest Income+	-10.5M	-7.2M	-2.9M	-1.4M	4.9M	1.2M	-7.4M	9.3M	49.6M	100.5M
Interest Income	7.9M	10.8M	20.3M	32M	32.2M	23.4M	17.4M	35.5M	67.2M	120.3M
Interest Expense	18.4M	18M	23.2M	33.4M	27.3M	22.2M	24.8M	26.2M	17.6M	19.8M
Other Income/Expense	46.5M	-77.6M	24.8M	-330.9M	-31.4M	-379.3M	91.6M	65M	-54.9M	169.4M
Pretax Income+	622.4M	737.9M	1.03B	761.4M	1.17B	916.7M	1.7B	1.77B	1.37B	1.55B
Pretax Margin %	0.25%	0.25%	0.3%	0.2%	0.27%	0.21%	0.33%	0.33%	0.27%	0.28%
Income Tax+	127.5M	168.4M	451.3M	39.2M	119.6M	93.3M	198.9M	245.5M	152.4M	152.1M
Effective Tax Rate %	0.8%	0.77%	0.6%	0.95%	0.9%	0.9%	0.88%	0.86%	1.02%	2.7%
Net Income+	494.9M	569.5M	622.1M	722.2M	1.05B	823.4M	1.5B	1.52B	1.4B	4.17B
Net Margin %	0.2%	0.19%	0.18%	0.19%	0.24%	0.19%	0.29%	0.28%	0.28%	0.77%
Net Income Growth %	-0.39%	0.15%	0.09%	0.16%	0.45%	-0.21%	0.83%	0.01%	-0.08%	1.98%
Net Income (Continuing)	494.9M	569.5M	583.6M	722.2M	1.05B	823.4M	1.5B	1.52B	1.22B	1.4B
Discontinued Operations	0	0	0	0	0	0	0	0	179.4M	2.77B
Minority Interest	0	0	0	0	0	0	0	0	69.4M	64.5M
EPS (Diluted)+	0.75	0.87	0.96	1.13	1.64	1.30	2.38	2.44	2.30	6.97
EPS Growth %	-0.4%	0.16%	0.1%	0.18%	0.45%	-0.21%	0.83%	0.03%	-0.06%	2.03%
EPS (Basic)	0.77	0.89	0.98	1.15	1.68	1.32	2.41	2.46	2.31	6.98
Diluted Shares Outstanding	660.9M	653.4M	647.7M	640.8M	636.6M	631.9M	631.2M	624.2M	609.4M	599.3M
Basic Shares Outstanding	646.5M	639M	632.7M	627.6M	624.9M	622.6M	623.3M	619M	606.7M	597.7M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	2.05B	2.24B	2.53B	2.29B	2.98B	3.09B	3.18B	3.1B	4.04B	6.29B
Cash & Short-Term Investments	1.22B	1.27B	1.34B	956.5M	1.52B	1.4B	1.47B	1.22B	1.63B	3.98B
Cash Only	718.4M	930.1M	818.3M	714.1M	1.18B	1.18B	862.8M	769M	1.13B	3.05B
Short-Term Investments	506.3M	341M	519.2M	242.4M	337.8M	219.4M	604M	446.3M	500.5M	930.7M
Accounts Receivable	371.8M	414.6M	479.3M	537.3M	599.1M	602.8M	664.9M	699.1M	828.1M	727.4M
Days Sales Outstanding	54.42	51.06	50.93	52.68	50.29	50.16	46.38	47.41	60.33	48.81
Inventory	339.9M	396.6M	554.9M	607M	640.9M	802.3M	726.7M	875.5M	903.5M	1.09B
Days Inventory Outstanding	181.3	179.65	229.4	240.27	202.48	266.46	216.37	273.78	317.92	354.94
Other Current Assets	122.8M	111.8M	116.9M	131.8M	168M	208.2M	237.1M	195.9M	542.5M	374.4M
Total Non-Current Assets+	2.01B	2.27B	3.16B	3.04B	3.5B	4.15B	5.32B	5.2B	5.33B	6.77B
Property, Plant & Equipment	482.5M	580M	679.7M	867.5M	1.14B	1.49B	1.64B	1.73B	1.68B	1.78B
Fixed Asset Turnover	5.17x	5.11x	5.05x	4.29x	3.81x	2.95x	3.19x	3.12x	2.99x	3.05x
Goodwill	628.3M	626.1M	1.13B	1.11B	1.17B	1.17B	1.17B	1.16B	1.15B	1.78B
Intangible Assets	205.4M	204.8M	468M	343.2M	336.5M	331.4M	323.6M	285.2M	399.4M	1.18B
Long-Term Investments	379.9M	532.1M	567M	506.3M	585.5M	801.6M	1.83B	1.24B	583.9M	307.9M
Other Non-Current Assets	131.8M	123.2M	108.9M	33.6M	101.8M	119.6M	110.8M	299.1M	774.3M	732.4M
Total Assets+	4.06B	4.51B	5.7B	5.32B	6.49B	7.24B	8.5B	8.29B	9.36B	13.06B
Asset Turnover	0.61x	0.66x	0.60x	0.70x	0.67x	0.61x	0.62x	0.65x	0.54x	0.42x
Asset Growth %	0.15%	0.11%	0.26%	-0.07%	0.22%	0.12%	0.17%	-0.02%	0.13%	0.39%
Total Current Liabilities+	476.2M	532.5M	1.4B	876.6M	902.4M	893.9M	1.03B	1.02B	1.2B	1.51B
Accounts Payable	63.9M	97.1M	116.6M	134M	180.4M	196.5M	204.5M	201.9M	186.6M	197.4M
Days Payables Outstanding	34.08	43.98	48.2	53.04	56.99	65.26	60.89	63.14	65.66	64.48
Short-Term Debt	0	0	598M	0	0	0	0	0	0	0
Deferred Revenue (Current)	0	0	0	0	0	0	0	0	0	1000K
Other Current Liabilities	219.2M	234.1M	349.1M	434M	338.9M	290.5M	342.7M	305M	530.2M	442.7M
Current Ratio	4.30x	4.21x	1.81x	2.61x	3.31x	3.46x	3.08x	3.03x	3.38x	4.18x
Quick Ratio	3.59x	3.46x	1.41x	1.92x	2.60x	2.56x	2.38x	2.17x	2.62x	3.45x
Cash Conversion Cycle	201.64	186.72	232.12	239.91	195.78	251.36	201.86	258.05	312.59	339.27
Total Non-Current Liabilities+	1.08B	1.36B	1.3B	1.31B	1.44B	1.77B	1.63B	1.46B	1.45B	1.49B
Long-Term Debt	596.9M	822.3M	438.4M	593.8M	594.4M	595M	595.7M	596.3M	597M	597.7M
Capital Lease Obligations	0	0	0	0	58.9M	72.7M	69.1M	69.5M	65.2M	78.9M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	480.1M	536.2M	851.8M	712.9M	784.1M	1.1B	969.6M	797.6M	786.2M	810.6M
Total Liabilities	1.56B	1.89B	2.7B	2.18B	2.34B	2.66B	2.67B	2.49B	2.64B	2.99B
Total Debt+	596.9M	822.3M	1.04B	593.8M	678.8M	694.9M	690.3M	691.3M	685.1M	700M
Net Debt	-121.5M	-107.8M	218.1M	-120.3M	-500.3M	-488.3M	-172.5M	-77.7M	-447.2M	-2.35B
Debt / Equity	0.24x	0.31x	0.35x	0.19x	0.16x	0.15x	0.12x	0.12x	0.10x	0.07x
Debt / EBITDA	0.93x	0.93x	0.95x	0.51x	0.52x	0.49x	0.39x	0.37x	0.44x	0.46x
Net Debt / EBITDA	-0.19x	-0.12x	0.20x	-0.10x	-0.38x	-0.34x	-0.10x	-0.04x	-0.28x	-1.53x
Interest Coverage	31.30x	45.31x	43.54x	32.70x	43.88x	58.38x	64.94x	64.98x	81.10x	69.63x
Total Equity+	2.5B	2.62B	2.99B	3.14B	4.15B	4.57B	5.84B	5.81B	6.72B	10.06B
Equity Growth %	0.14%	0.05%	0.14%	0.05%	0.32%	0.1%	0.28%	-0.01%	0.16%	0.5%
Book Value per Share	3.79	4.01	4.62	4.90	6.52	7.24	9.25	9.30	11.03	16.79
Total Shareholders' Equity	2.5B	2.62B	2.99B	3.14B	4.15B	4.57B	5.84B	5.81B	6.65B	10B
Common Stock	239.1M	242.6M	212M	215.2M	218.1M	636.4M	642M	646.3M	650.5M	654.8M
Retained Earnings	3.34B	3.91B	2B	2.69B	3.74B	4.57B	6.07B	7.59B	8.99B	13.17B
Treasury Stock	-1.84B	-2.5B	-252.1M	-1.02B	-1.28B	-1.9B	-2.42B	-4.14B	-5.02B	-6.19B
Accumulated OCI	-182.6M	-198.4M	-132.7M	-138.5M	-156M	-161.1M	-157.7M	-254.9M	-242.8M	-244.5M
Minority Interest	0	0	0	0	0	0	0	0	69.4M	64.5M

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	549.7M	704.4M	1B	926.8M	1.18B	1.05B	1.73B	1.22B	895.8M	542.3M
Operating CF Margin %	0.22%	0.24%	0.29%	0.25%	0.27%	0.24%	0.33%	0.23%	0.18%	0.1%
Operating CF Growth %	-0.46%	0.28%	0.42%	-0.07%	0.27%	-0.11%	0.64%	-0.3%	-0.26%	-0.39%
Net Income	494.9M	569.5M	583.6M	722.2M	1.05B	823.4M	1.5B	1.52B	1.4B	4.17B
Depreciation & Amortization	65.8M	71.2M	81.9M	77.4M	89.3M	107.2M	134.8M	139.6M	144.9M	155.2M
Stock-Based Compensation	49.9M	56.9M	61.6M	71M	81.3M	92.6M	109.3M	126.8M	139.4M	162.3M
Deferred Taxes	-95M	-37.4M	17.8M	-27.3M	12.1M	-49.4M	-41.4M	-254.5M	-272.1M	-323.4M
Other Non-Cash Items	-30.3M	-21.9M	21.6M	126.1M	154.1M	38.3M	-119M	105.8M	7.5M	-3.36B
Working Capital Changes	64.4M	66.1M	234.2M	-42.6M	-204.3M	42.2M	145.3M	-421.4M	-526.3M	-259.3M
Change in Receivables	-38.3M	-56.7M	-3.9M	-13M	-94.8M	283.9M	-112.4M	-84.1M	-141.2M	121.2M
Change in Inventory	-67.7M	-65.6M	-124M	-65.7M	-105.4M	-120.6M	19M	-213.4M	-289M	-256.1M
Change in Payables	29.4M	74M	85.2M	192.5M	-63.5M	-84.5M	195.2M	-21.4M	146M	89.5M
Cash from Investing+	-316.1M	-211.7M	-647.2M	76.7M	-595.8M	-531.1M	-1.72B	252.3M	173.8M	2.31B
Capital Expenditures	-106.5M	-217.4M	-175.5M	-241.7M	-278.4M	-407.3M	-329.8M	-264.8M	-266.3M	-282.4M
CapEx % of Revenue	0.04%	0.07%	0.05%	0.06%	0.06%	0.09%	0.06%	0.05%	0.05%	0.05%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	2.4M	1.2M	-43.1M	-4.8M	-24M	-446.4M	-359.3M	-63.1M	-75M	3.75B
Cash from Financing+	-158.6M	-268.5M	-473.2M	-1.1B	-115.6M	-486.9M	-356.3M	-1.58B	-711M	-983M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	119.6M	171.7M	113.8M	131.6M	157.7M	139.3M	158.3M	142.8M	168.9M	176.4M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	443.2M	487M	825.2M	685.1M	901M	647M	1.4B	953.4M	629.5M	289.9M
FCF Margin %	0.18%	0.16%	0.24%	0.18%	0.21%	0.15%	0.27%	0.18%	0.13%	0.05%
FCF Growth %	-0.52%	0.1%	0.69%	-0.17%	0.32%	-0.28%	1.17%	-0.32%	-0.34%	-0.54%
FCF per Share	0.67	0.75	1.27	1.07	1.42	1.02	2.22	1.53	1.03	0.48
FCF Conversion (FCF/Net Income)	1.11x	1.24x	1.61x	1.28x	1.13x	1.28x	1.15x	0.80x	0.64x	0.13x
Interest Paid	14.1M	16.1M	19.9M	30.1M	19.9M	19.9M	20.2M	19.3M	19.9M	19.6M
Taxes Paid	86.9M	99.9M	143.7M	223.7M	61.5M	197.9M	182.5M	504.1M	470.1M	1.2B

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	21.08%	22.24%	22.16%	23.54%	28.73%	18.88%	28.88%	26.14%	22.39%	49.75%
Return on Invested Capital (ROIC)	19.12%	25%	26.47%	26.29%	26.95%	25.14%	24.78%	22.41%	17.84%	14.78%
Gross Margin	72.56%	72.81%	74.3%	75.23%	73.43%	74.94%	76.57%	78.31%	79.3%	79.46%
Net Margin	19.85%	19.22%	18.11%	19.4%	24.08%	18.77%	28.73%	28.28%	27.99%	76.75%
Debt / Equity	0.24x	0.31x	0.35x	0.19x	0.16x	0.15x	0.12x	0.12x	0.10x	0.07x
Interest Coverage	31.30x	45.31x	43.54x	32.70x	43.88x	58.38x	64.94x	64.98x	81.10x	69.63x
FCF Conversion	1.11x	1.24x	1.61x	1.28x	1.13x	1.28x	1.15x	0.80x	0.64x	0.13x
Revenue Growth	7.35%	18.85%	15.91%	8.37%	16.79%	0.88%	19.29%	2.86%	-6.92%	8.57%

Revenue by Segment

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Transcatheter Heart Valves	1.18B	1.63B	2.03B	2.29B	2.74B	2.86B	3.42B	3.52B	3.88B	4.11B
Transcatheter Heart Valves Growth	-	37.97%	24.48%	12.80%	19.73%	4.36%	19.78%	2.80%	10.28%	5.83%
Surgical Heart Valve Therapy	785M	774.9M	807.1M	761.6M	841.7M	761.8M	889.1M	893.1M	999.3M	981.3M
Surgical Heart Valve Therapy Growth	-	-1.29%	4.16%	-5.64%	10.52%	-9.49%	16.71%	0.45%	11.89%	-1.80%
Transcatheter Mitral And Tricuspid Therapies	-	-	-	-	28.2M	41.8M	86M	116.1M	197.6M	352.1M
Transcatheter Mitral And Tricuspid Therapies Growth	-	-	-	-	-	48.23%	105.74%	35.00%	70.20%	78.19%
Critical Care	528.4M	560.3M	601M	674.5M	740.2M	725.4M	834.9M	855M	928.1M	-
Critical Care Growth	-	6.04%	7.26%	12.23%	9.74%	-2.00%	15.10%	2.41%	8.55%	-

Revenue by Geography

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
UNITED STATES	1.26B	1.62B	1.91B	2.06B	2.53B	2.52B	2.96B	3.13B	3.51B	3.21B
UNITED STATES Growth	-	27.94%	18.07%	7.74%	23.23%	-0.63%	17.73%	5.72%	12.01%	-8.63%
Europe	717.3M	749M	831M	885.1M	941.2M	973.6M	1.19B	1.17B	1.33B	1.32B
Europe Growth	-	4.42%	10.95%	6.51%	6.34%	3.44%	22.26%	-1.30%	13.59%	-0.96%
World	267.3M	289.7M	346.4M	385.6M	429.4M	435.8M	550.2M	601.4M	709.2M	572M
World Growth	-	8.38%	19.57%	11.32%	11.36%	1.49%	26.25%	9.31%	17.92%	-19.35%
JAPAN	246.2M	309.3M	350.3M	396.8M	444.7M	460.1M	528.9M	473.6M	452.4M	339.8M
JAPAN Growth	-	25.63%	13.26%	13.27%	12.07%	3.46%	14.95%	-10.46%	-4.48%	-24.89%

Frequently Asked Questions

Valuation & Price

Edwards Lifesciences Corporation (EW) has a price-to-earnings (P/E) ratio of 12.0x. This may indicate the stock is undervalued or faces growth challenges.

Growth & Financials

Edwards Lifesciences Corporation (EW) reported $5.88B in revenue for fiscal year 2024. This represents a 251% increase from $1.68B in 2011.

Edwards Lifesciences Corporation (EW) grew revenue by 8.6% over the past year. This is steady growth.

Yes, Edwards Lifesciences Corporation (EW) is profitable, generating $1.36B in net income for fiscal year 2024 (76.7% net margin).

Dividend & Returns

Edwards Lifesciences Corporation (EW) has a return on equity (ROE) of 49.8%. This is excellent, indicating efficient use of shareholder capital.

Edwards Lifesciences Corporation (EW) generated $804.2M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

US Stock Screener

...